Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ABVC BioPharma, Inc. - Common Stock (NQ:ABVC)

1.460 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	10
Open	1.460
Bid (Size)	1.270 (1,000)
Ask (Size)	2.250 (100)
Prev. Close	1.460
Today's Range	1.460 - 1.460
52wk Range	0.6100 - 5.480
Shares Outstanding	23,541,824
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ABVC BioPharma Reports 2025 Form 10-K

March 03, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ABVC BioPharma Reports 2025 Form 10-K

March 03, 2026

Total Assets Increase 179% to $21.06 Million as Company Strengthens Asset-Backed Licensing Model

Via TheNewswire.com

Performance

YTD	-33.3%	-33.3%
1 Month	-15.6%	-15.6%
3 Month	-31.1%	-31.1%
6 Month	-46.3%	-46.3%
1 Year	+130.9%	+130.9%

More News

ABVC BioPharma Provides Corporate and Structural Update

February 24, 2026

Via NewMediaWire

ABVC BioPharma Provides Corporate and Structural Update

February 24, 2026

Via TheNewswire.com

ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States

December 02, 2025

Via NewMediaWire

ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States

December 02, 2025

Via TheNewswire.com

ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030

November 26, 2025

Via NewMediaWire

November 26, 2025

Via TheNewswire.com

ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received

November 21, 2025

Via NewMediaWire

ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received

November 21, 2025

Via TheNewswire.com

ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million

November 18, 2025

Via NewMediaWire

ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million

November 18, 2025

Via TheNewswire.com

ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025

November 03, 2025

Via NewMediaWire

ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025

November 03, 2025

Via TheNewswire.com

ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950

October 31, 2025

Via NewMediaWire

ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950

October 31, 2025

Via TheNewswire.com

ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology

October 17, 2025

Via TheNewswire.com

ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology

October 17, 2025

Via NewMediaWire

ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production

October 08, 2025

Via NewMediaWire

ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production

October 08, 2025

Via TheNewswire.com

ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model

September 19, 2025

Via TheNewswire.com

ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model

September 19, 2025

Via NewMediaWire

ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025

August 29, 2025

Via NewMediaWire

ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025

August 29, 2025

Via TheNewswire.com

BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration

August 27, 2025

Via NewMediaWire

Frequently Asked Questions

Is ABVC BioPharma, Inc. - Common Stock publicly traded?

Yes, ABVC BioPharma, Inc. - Common Stock is publicly traded.

What exchange does ABVC BioPharma, Inc. - Common Stock trade on?

ABVC BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ABVC BioPharma, Inc. - Common Stock?

The ticker symbol for ABVC BioPharma, Inc. - Common Stock is ABVC on the Nasdaq Stock Market

What is the current price of ABVC BioPharma, Inc. - Common Stock?

The current price of ABVC BioPharma, Inc. - Common Stock is 1.460

When was ABVC BioPharma, Inc. - Common Stock last traded?

The last trade of ABVC BioPharma, Inc. - Common Stock was at 03/09/26 04:00 PM ET

What is the market capitalization of ABVC BioPharma, Inc. - Common Stock?

The market capitalization of ABVC BioPharma, Inc. - Common Stock is 34.37M

How many shares of ABVC BioPharma, Inc. - Common Stock are outstanding?

ABVC BioPharma, Inc. - Common Stock has 34M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.